About OcellO
OcellO is a company based in Leiden (Netherlands) founded in 2011 was acquired by Crown Bioscience in May 2021.. OcellO offers products and services including PDX Models, Genomics Services, Proteomics Services, CRISPR/Cas9 Services, and Bioanalytical Services. OcellO operates in a competitive market with competitors including Reaction Biology, ImmunoSCAPE, PhenoVista, Discovery Biomed and BCI Pharma, among others.
- Headquarter Leiden, Netherlands
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$325.75 K (USD), Grant
Jan 01, 2021
-
Investors
Crown Bioscience
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Crown Bioscience
(May 05, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OcellO
OcellO offers a comprehensive portfolio of products and services, including PDX Models, Genomics Services, Proteomics Services, CRISPR/Cas9 Services, and Bioanalytical Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Preclinical models for tumor drug testing and research
DNA sequencing and analysis for biomarker discovery
Mass spectrometry-based analysis for protein studies
Gene editing tools for cell line development
Testing for biomarkers and drug responses
Funding Insights of OcellO
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $325,747
-
First Round
First Round
(01 Sep 2017)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Grant - OcellO | Valuation |
investors |
|
| Feb, 2018 | Amount | Grant - OcellO | Valuation |
investors |
|
| Sep, 2017 | Amount | Grant - OcellO | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OcellO
OcellO has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Crown Bioscience and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Cancer and CVMD drugs are developed using PDX models.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OcellO
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OcellO
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ocello Comparisons
Competitors of OcellO
OcellO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Reaction Biology, ImmunoSCAPE, PhenoVista, Discovery Biomed and BCI Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling
|
|
| domain | founded_year | HQ Location |
High-dimensional immune profiling services are delivered via proprietary platform.
|
|
| domain | founded_year | HQ Location |
A CRO that provides phenotypic assay development and screening services.
|
|
| domain | founded_year | HQ Location |
Custom human cell engineering and drug discovery services are provided.
|
|
| domain | founded_year | HQ Location |
Contract research services in cancer and neuroinflammation are offered.
|
|
| domain | founded_year | HQ Location |
Specialised CRO offering a range of screening platforms for cardiac safety testing, ion channel profiling and in vitro HTS screening
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about OcellO
When was OcellO founded?
OcellO was founded in 2011 and raised its 1st funding round 6 years after it was founded.
Where is OcellO located?
OcellO is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
What does OcellO do?
OcellO is a CRO that provides 3D screening services for drug discovery. It has a proprietary high throughput system for 3D imaging and phenotypic profiling that enables better quantification of complex biological phenomena combined with clinically relevant endpoints. Based on this platform, the company offers several drug screening and discovery services, including development of target-specific and immuno-oncology assays for screening drugs, phenotypic screening in disease models of interest and compound profiling, as well as a specialized drug candidate testing platform for polycystic kidney disease. In addition, OcellO offers in vitro 3D cell culture assays of patient-derived xenograft (PDX) mouse models for lead optimization, in partnership with Charles River Laboratories.
Who are the top competitors of OcellO?
OcellO's top competitors include ImmunoSCAPE, Quantumcyte and Reaction Biology.
What products or services does OcellO offer?
OcellO offers PDX Models, Genomics Services, Proteomics Services, CRISPR/Cas9 Services, and Bioanalytical Services.
Who are OcellO's investors?
OcellO has 2 investors. Key investors include Crown Bioscience, and European Union.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.